Plain-English translation of NCT07410676 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called EBNK-001, which uses natural killer cells—a type of immune cell that your body naturally uses to fight cancer. In this study, researchers will give you specially prepared natural killer cells along with a protein called interleukin-15 to help them survive and work better. Some participants will also receive an immunotherapy drug called pembrolizumab to boost the immune response further.
Many people with advanced cancer run out of treatment options because their tumors stop responding to standard therapies. This medication aims to harness the body's immune system in a new way to fight cancers that have become resistant to other treatments.
You likely qualify if…
You likely don't qualify if…
You will first receive a short course of chemotherapy to prepare your body for the treatment. Then you'll receive weekly infusions of the natural killer cells for three consecutive weeks, followed by the helper protein to support cell survival. You may also receive the additional immunotherapy drug depending on which group you're in. Throughout the trial, you'll have regular clinic visits and scans to check how the treatment is working, with follow-up lasting at least 12 months.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China